eatments. Almost half of the enrolled patients remain in the study.
"These results with pazopanib are very encouraging," said lead investigator Dr. Thomas Hutson, Baylor Sammons/Texas Oncology PA, Dallas, Texas. "The high response rates seen so far in this study show clear clinical activity in advanced or metastatic renal cell carcinoma, and a number of ongoing studies also demonstrate therapeutic promise in several other tumor types."
The most frequent adverse events (AEs) were diarrhea, fatigue, hair color change, nausea, and hypertension. Pazopanib had a low incidence of hand-foot syndrome (10%), rash (12%), hemorrhage (9%), and mucositis (5%). Please see safety considerations below.
The incidence of RCC is rising throughout the world with 208,000 new cases diagnosed annually. Although patients with early-stage disease can potentially be cured with surgery, many will either experience a recurrence after surgery or have advanced or metastatic disease at the time of initial presentation. RCC is generally resistant to standard chemotherapy, and immunotherapeutic regimens using recombinant human interleukin-2 (IL-2) and recombinant human interferon a-2b (IFN-a), either alone or in combination, have been widely used in patients with advanced disease.
Although high-dose IL-2 has shown promise with durable complete remissions observed in 7% of patients, toxicity has limited its widespread use. Lower dose cytokine therapies have not shown the same magnitude of response and are also limited by their toxicity. Recently, several anti-angiogenesis drugs, including sunitinib, sorafenib and bevacizumab have demonstrated clinical activity in patients with advanced or metastatic RCC. Although targeted therapies have advanced the treatment of advanced or metastatic RCC, complete and durable responses are not achieved in the majority of patients and a need remains for new treatment options.
"These results clearlPage: 1 2 3 4 Related medicine news :1
. Experimental treatment for Ebola Virus Shows promising results in mice2
. New Prostate Cancer Vaccine Shows Promise3
. Ebola Treatment Shows Promise4
. New Drug Shows Significant Improvement In HIV-related Heart Condition5
. Greek Study Shows Living In The Hills May Be Healthier
. Research Shows Carbon Monoxide Prevents Inflammations7
. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly8
. Novartis MS Drug Shows Promising Results9
. MRI Shows Emotional Changes During Menstrual Cycle 10
. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia 11
. AIDS drug GS 9137 Shows Promise